Imaging Modalities for Biliary and Pancreatic Disorders

Recommendations for Imaging

• The American College of Radiology recommends MRCP as a second-line imaging modality after ultrasound for evaluating jaundice, suspected biliary obstruction, or pancreaticobiliary disorders, particularly in cases with intermediate probability of bile duct stones or when non-invasive visualization of the biliary tree is needed 1
• MRCP is recommended for suspected primary sclerosing cholangitis, primary biliary cirrhosis, extrahepatic biliary strictures, and pancreatic ductal abnormalities, as recommended by the American College of Radiology 1
• For pregnant women and pediatric patients, MRCP is preferred due to radiation concerns, with MRCP recommended as a first-line advanced imaging modality for biliary/pancreatic pathology in pregnant women 2
• The diagnostic and treatment algorithm for bile duct stones should begin with transabdominal ultrasound and liver function tests, followed by MRCP or EUS for intermediate probability cases, and proceed to ERCP or surgical extraction for confirmed stones, as recommended by the National Institute for Health and Care Excellence (NICE) guidelines 3

Patient Evaluation and Categorization

• Patients should be categorized based on probability of bile duct stones, with high probability defined as bile duct stone visible on ultrasound, features of cholangitis, or pain with duct dilation and jaundice in patients with gallstone history, intermediate probability as bile duct dilation with normal LFTs or abnormal LFTs with normal caliber biliary system, and low probability as normal ultrasound and LFTs, with a sensitivity of 73% and specificity of 91% for ultrasound 3
• Transabdominal ultrasound and liver function tests are recommended as first-line imaging, with normal results not excluding bile duct stones if clinical suspicion remains high, as supported by the American Association for the Study of Liver Diseases 3

Diagnostic Modalities

• MRCP is recommended as the safest and most acceptable test in most cases, due to its wide availability and non-invasive nature, with a pooled sensitivity of 86% and specificity of 94% for diagnosing Primary Sclerosing Cholangitis (PSC) and a sensitivity of 93% and specificity of 96% for detecting causes of biliary obstruction 4, 5, 3
• EUS is an alternative option, particularly for patients with contraindications to MRCP, with a sensitivity of 95% and specificity of 97% 6, 3
• The following table compares the sensitivity, specificity, advantages, and disadvantages of different diagnostic modalities:

Therapeutic Interventions

• ERCP should be performed in facilities with high-quality training and adequately resourced facilities, with propofol sedation or general anesthesia available for selected patients to improve tolerability and success rates, as recommended by the American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 3, 7
• If bile duct stones are confirmed, patients should proceed to ERCP for therapeutic stone extraction, and consider subsequent cholecystectomy to prevent recurrence, as recommended by the European Association for the Study of the Liver and the American Society for Gastrointestinal Endoscopy (ASGE) 3, 8, 7
• Medical management with ursodeoxycholic acid (8-10 mg/kg/day in 2-3 divided doses) may be considered for patients who cannot undergo surgery, although the strength of evidence for this recommendation is not specified, as recommended by the European Association for the Study of the Liver 8

Special Considerations

• In cases of suspected small duct PSC, liver biopsy is required as MRCP and ERCP may not visualize peripheral duct changes, as recommended by the American Association for the Study of Liver Diseases 4
• For trauma cases, MRCP is recommended for stable patients with suspected pancreatic or biliary injury, as recommended by the American Association for the Study of Liver Diseases 2
• Annual abdominal ultrasound is recommended to assess liver morphology and echogenicity, portal vein wall thickness, signs of portal hypertension, and presence of focal lesions in patients with stable LFTs on ursodeoxycholic acid therapy, as recommended by the European Association for the Study of the Liver 8